Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
Frequently Asked Questions
[Image: Ketamine for depression educational article visual]
Educational content only. Treatment decisions should be made with a licensed clinician.
Ketamine for depression may help some adults with treatment-resistant depression, but it is not a universal or first-line treatment. Ketamine is an anesthetic medicine that has also been studied for rapid antidepressant effects at lower, clinician-directed doses. The FDA-approved nasal spray esketamine is used with an oral antidepressant for certain adults with treatment-resistant depression and for depressive symptoms in adults with acute suicidal ideation or behavior, under specific prescribing and monitoring requirements.
For anyone considering this option, the practical question is not simply whether ketamine can work. It is whether a qualified clinician thinks it fits your diagnosis, medical history, current medicines, safety needs, and wider depression treatment plan.
Quick Answer
Ketamine can reduce depressive symptoms quickly for some people, particularly those with treatment-resistant depression, but response and duration vary. Esketamine is FDA-approved for limited depression indications, while other ketamine use for depression may be off-label. Assessment, monitoring, and follow-up care matter as much as the treatment itself.
What ketamine treatment for depression means
Ketamine is a dissociative anesthetic that affects glutamate signaling, including the N-methyl-D-aspartate, or NMDA, receptor. Researchers are still studying how those effects relate to changes in depression symptoms. A proposed biological mechanism is not a guarantee of benefit for an individual patient.
Esketamine, sold as Spravato, is a nasal spray related to ketamine. The FDA prescribing information for Spravato describes its approved uses, contraindications, risks, and required observation after administration. Because sedation, dissociation, and respiratory depression can occur, the labeling requires administration under supervision and monitoring for at least two hours.
Racemic ketamine is the form commonly used as an anesthetic. Some clinicians use it off-label for depression, often by intravenous, intramuscular, oral, or sublingual routes. Off-label use means the FDA has not approved that product and route for depression. It does not, by itself, tell you whether care is appropriate. It does mean the clinician should clearly explain the treatment plan, evidence, alternatives, and safety approach.
What the evidence can and cannot tell you
The FDA label defines treatment-resistant depression for esketamine studies as inadequate response to at least two different antidepressants of adequate dose and duration in the current depressive episode.
According to the FDA-approved Spravato prescribing information, patients must be monitored for at least two hours after administration because of sedation, dissociation, and respiratory depression risk.
How quickly can ketamine help?
Some studies have found symptom improvement within hours or days after ketamine treatment, which differs from the usual onset timeline of many standard antidepressants. That rapid effect is clinically important, but it should not be interpreted as an immediate cure or a substitute for urgent emergency care.
According to a 2024 National Institute of Mental Health overview, if you are in immediate danger or having thoughts of suicide, call or text 988 in the United States or contact local emergency services. A clinician should determine whether urgent evaluation, a higher level of care, medication changes, psychotherapy, or another intervention is needed.
People may have no response, a partial response, or benefits that fade. A responsible treatment discussion includes how progress will be measured, what happens if symptoms worsen, and when the plan will be reassessed.
Compare low-dose options
Review routes, dosing discussions, and alternatives before speaking with a clinician.
Compare optionsKey Takeaway
Fast symptom change is possible for some people, but ketamine treatment should be part of a documented clinical plan with screening, monitoring, and follow-up.
Who may be a candidate?
Ketamine may be discussed when depression has not improved adequately with prior treatment, or when a specialist believes its potential benefits warrant consideration. A clinician needs to review the whole picture, including the diagnosis, past treatment response, current medicines, substance use history, cardiovascular history, pregnancy considerations, and ability to arrange safe transportation and support after treatment.
It may not be the right approach for everyone. For example, the Spravato label lists contraindications including aneurysmal vascular disease, arteriovenous malformation, and history of intracerebral hemorrhage. The label also warns that blood pressure can increase after dosing. These are examples of why a medical assessment cannot be replaced by an online questionnaire alone.
People with bipolar depression need particular diagnostic care. Depression can occur in bipolar disorder, but treatment decisions should be made with a clinician who can assess mood history and the risk of mood switching. Do not start, stop, or change psychiatric medication without prescriber guidance.
For a broader overview of the evidence and its limits, see our guide to ketamine research and evidence.
Potential advantages
- Some patients experience symptom improvement faster than with many conventional antidepressants.
- Esketamine has FDA-approved uses for specified forms of depression when used with an oral antidepressant.
- Treatment can create an opportunity to reassess symptoms and engage with a fuller care plan.
Important considerations
- Not everyone responds, and improvement may not last without an individualized maintenance plan.
- Ketamine can cause short-term effects such as dissociation, sedation, nausea, and increased blood pressure.
- Different formulations and routes have different evidence, oversight, and monitoring expectations.
What a safe treatment plan should cover
A credible plan starts with diagnosis and screening, not a promise of a particular outcome. Ask how the clinician will establish whether depression is treatment-resistant, review your medications, and coordinate with your existing mental health care when appropriate.
The plan should also explain the administration setting. For FDA-approved esketamine, the REMS program restricts dispensing and requires certified healthcare settings because of serious safety risks. Read the Spravato REMS program information to understand the program’s stated monitoring and distribution requirements.
Before any appointment, review drug interactions and contraindications with the treating clinician or pharmacist. Alcohol, sedatives, benzodiazepines, stimulants, and other medicines can affect safety or treatment decisions. The right action depends on your individual prescriptions and history, so do not make medication changes based on a general article.
After treatment, patients may need someone else to drive them home and should follow the clinician’s instructions about returning to work, driving, and other activities. The FDA label for esketamine advises patients not to drive or operate machinery until the next day after restful sleep.
Questions to bring to a ketamine consultation
- What diagnosis and prior treatment history make me a possible candidate?
- Which ketamine or esketamine formulation and route are you recommending, and why?
- What evidence supports this approach for my situation, and what are the alternatives?
- What medicines, alcohol, cannabis, or health conditions need review before treatment?
- How will you monitor blood pressure, sedation, dissociation, and mental health symptoms?
- How will we define response, decide on follow-up, and respond if my depression worsens?
How ketamine fits with other depression care
Ketamine is usually considered alongside, rather than apart from, the rest of a depression care plan. That plan may include medication management, psychotherapy, sleep and substance-use support, and treatment for related conditions. Some people also use integration-focused therapy to reflect on experiences and maintain helpful behavior changes. Read more about ketamine integration therapy and discuss whether it is relevant to your care.
Maintenance is a separate decision from initial treatment. There is no one schedule that fits every patient, and a schedule should be based on response, side effects, safety, and the specific product or protocol. Our overview of how many ketamine treatments may be needed explains why treatment frequency requires individualized clinical guidance.
If ketamine does not help, that result is useful clinical information, not a personal failure. Ask your clinician to reassess the diagnosis, treatment history, adherence, co-occurring conditions, and other evidence-based options. For people dealing with persistent symptomsnext steps for treatment-resistant depression may help frame that conversation.
Important
Ketamine can have serious risks and is not appropriate for self-treatment. If you have immediate safety concerns, suicidal thoughts with intent, or a plan to harm yourself, seek urgent help through 988 in the United States, local emergency services, or the nearest emergency department.
Learn More
Contact Low Dose Ketamine with questions about this educational resource or to share a correction.
Frequently Asked Questions
Ketamine affects glutamate signaling, including NMDA receptors, and researchers are studying how this may relate to rapid changes in depression symptoms. The mechanism is still being studied, and response differs from person to person.
Duration varies. Some people report temporary improvement, while others have no response or need an individualized ongoing care plan. A clinician should review benefits and risks over time rather than assume a fixed schedule.
Esketamine has an FDA-approved indication for depressive symptoms in adults with acute suicidal ideation or behavior when used with an oral antidepressant. It does not replace immediate safety assessment, crisis support, or hospitalization when those are needed.
Ketamine may act more quickly for some patients, while traditional antidepressants are commonly used as ongoing treatments and often take longer to show benefit. A clinician can compare expected benefits, risks, monitoring, and alternatives for your circumstances.
Share
Related Reading
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.